He W, Tong L, Yuan Y, Yang X, Yang W, Pan X
Front Pharmacol. 2025; 16:1448095.
PMID: 40061962
PMC: 11885501.
DOI: 10.3389/fphar.2025.1448095.
Zhu X, Zhao L, Li B, Cheng Y, Sun H
J Hepatocell Carcinoma. 2025; 12:399-413.
PMID: 40034975
PMC: 11873029.
DOI: 10.2147/JHC.S504457.
Miwa C, Ogasawara S, Yonemoto T, Yumita S, Okubo T, Nakagawa M
Cancer Med. 2025; 14(5):e70642.
PMID: 40013724
PMC: 11866308.
DOI: 10.1002/cam4.70642.
Fadlallah H, El Masri D, Bahmad H, Abou-Kheir W, El Masri J
Med Sci (Basel). 2025; 13(1).
PMID: 39982238
PMC: 11843904.
DOI: 10.3390/medsci13010013.
Hsu Y, Wu M, Weng M, Lee Y, Chou H, Lee H
J Immunother Cancer. 2025; 13(2).
PMID: 39979070
PMC: 11843001.
DOI: 10.1136/jitc-2024-010472.
Stereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer.
Hoffmeister-Wittmann P, Hoegen-Sassmannshausen P, Wicklein L, Weykamp F, Seidensaal K, Springfeld C
Radiat Oncol. 2025; 20(1):23.
PMID: 39966902
PMC: 11834390.
DOI: 10.1186/s13014-025-02594-y.
Hepatocellular carcinoma recurrence: Predictors and management.
Abdelhamed W, El-Kassas M
Liver Res. 2025; 7(4):321-332.
PMID: 39958776
PMC: 11791921.
DOI: 10.1016/j.livres.2023.11.004.
An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy.
Chen Y, Pasquier D, Verstappen D, Woodruff H, Lambin P
J Cancer Res Clin Oncol. 2025; 151(2):84.
PMID: 39948208
PMC: 11825551.
DOI: 10.1007/s00432-025-06119-8.
Identification of the entosis-related prognostic signature and tumour microenvironment in hepatocellular carcinoma on the basis of bioinformatics analysis and experimental validation.
Wu C, Fang S, Wu L, Mi Z, Yin Y, Liao Y
Clin Exp Med. 2025; 25(1):55.
PMID: 39937284
PMC: 11821697.
DOI: 10.1007/s10238-025-01580-8.
Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.
Takamoto T, Mihara Y, Nishioka Y, Ichida A, Kawaguchi Y, Akamatsu N
Int J Clin Oncol. 2025; 30(3):417-426.
PMID: 39907863
PMC: 11842484.
DOI: 10.1007/s10147-025-02703-7.
Recurrence and survival after robotic vs laparoscopic liver resection in very-early to early-stage (BCLC 0-A) hepatocellular carcinoma.
Bernardi L, Balzano E, Roesel R, Senatore A, Pezzati D, Catalano G
Surg Endosc. 2025; 39(3):2116-2128.
PMID: 39904789
PMC: 11870908.
DOI: 10.1007/s00464-025-11553-3.
Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report.
Rinka K, Kioka K, Amano Y, Nakai T, Kawasaki Y, Kawada N
J Med Case Rep. 2025; 19(1):38.
PMID: 39871286
PMC: 11770955.
DOI: 10.1186/s13256-025-05040-5.
All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement.
Lanza C, Ascenti V, Amato G, Pellegrino G, Triggiani S, Tintori J
J Clin Med. 2025; 14(2).
PMID: 39860320
PMC: 11766109.
DOI: 10.3390/jcm14020314.
Dual-drug loaded chondroitin sulfate embolization beads enhance TACE therapy for HCC by integrating embolization, chemotherapy, and anti-angiogenesis.
Huang J, Yang R, Long H, Kong J, Shao G, Xiong F
Mater Today Bio. 2025; 30():101419.
PMID: 39845443
PMC: 11751543.
DOI: 10.1016/j.mtbio.2024.101419.
Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis.
Zhao Z, Jiang X, Wen S, Hao Y
Front Pharmacol. 2025; 15():1499269.
PMID: 39840082
PMC: 11747745.
DOI: 10.3389/fphar.2024.1499269.
Comprehensive analysis of protein post-translational modifications reveals PTPN2-STAT1-AOX axis-mediated tumor progression in hepatocellular carcinomas.
Wang J, Lou Y, Peng X, Ye M, Cao W, Wu J
Transl Oncol. 2025; 53:102275.
PMID: 39837058
PMC: 11788854.
DOI: 10.1016/j.tranon.2025.102275.
Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study.
Ronot M, Loffroy R, Arnold D, Greget M, Sengel C, Pinaquy J
Cardiovasc Intervent Radiol. 2025; 48(2):205-220.
PMID: 39809885
PMC: 11790776.
DOI: 10.1007/s00270-024-03955-y.
Predicting prognosis prior to the combination of atezolizumab and bevacizumab on unresectable HCC: Analysis and comparison of tumor heterogeneity at CT and Gd-EOB-DTPA hepatobiliary MR imaging.
Kwon H, Kang E, Kim S, Baeck Y, Bark I, Cho J
Medicine (Baltimore). 2024; 103(49):e40769.
PMID: 39654244
PMC: 11630974.
DOI: 10.1097/MD.0000000000040769.
A Decade of Experience Between Open and Minimally Invasive Hepatectomies for Hepatocellular Carcinoma.
Park A, Kwon Y, Savsani K, Sharma A, Sambommatsu Y, Imai D
Medicina (Kaunas). 2024; 60(11).
PMID: 39596922
PMC: 11596858.
DOI: 10.3390/medicina60111737.
Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease.
Rzeniewicz K, Sharma R
World J Clin Oncol. 2024; 15(11):1394-1403.
PMID: 39582617
PMC: 11514420.
DOI: 10.5306/wjco.v15.i11.1394.
